Workflow
Biotechnology
icon
Search documents
Viking Therapeutics: What's Next?
The Motley Fool· 2025-08-26 10:15
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.Viking Therapeutics (VKTX -0.69%) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2 results from its oral VK2735, dropping from $42 to around $26 as investors fixated on tolerability concerns.Look closer, though. At just 13 weeks, VK2735's 12.2% weight loss signal is unusually strong ...
Scenic Enters License and Research Agreement with Alnylam
GlobeNewswire News Room· 2025-08-26 09:00
 Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. "Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets," said Vin ...
港股评级汇总 | 高盛维持东方甄选沽售评级
Xin Lang Cai Jing· 2025-08-26 07:47
中信里昂:维持泡泡玛特跑赢大市评级 升目标价至368港元 智通财经8月26日讯(编辑 童古 汤赞淇)以下为各家机构对港股的最新评级和目标价: 高盛:维持东方甄选沽售评级 升目标价至9港元 高盛就东方甄选(01797.HK)发布研报称,下调公司2026至2027财年GMV预测1%至3%,受益于自营品牌 产品GMV贡献提升,将收入预测上调最多10%,2026至2027财年经调整净利润率预测上调0.2%和1%, 目标价上调至9港元。因基本面持续疲软,加上估值较贵,该行维持沽售评级。 中金公司就布鲁可(00325.HK)发布研报称,公司2025年上半年收入同比增长27.9%至13.4亿元,经调整 净利润同比增长10%。尽管利润率因低毛利产品占比提升及费用投入加大而承压,但海外业务收入同比 大增899%,产品结构持续优化,IP商业化进程稳步推进。中金公司看好其全人群、全价位、全球化战 略带来的长期成长潜力,维持"跑赢行业"评级,目标价135港元。 海通国际:维持金斯瑞生物科技优于大市评级 海通国际就金斯瑞生物科技(01548.HK)发布研报称,公司2025年上半年收入同比增长81.9%至5.19亿美 元,持续经营业务经 ...
CorMedix: The Undervalued Breakthrough
Seeking Alpha· 2025-08-26 06:41
Core Insights - CorMedix has recently achieved profitability after years of losses, marking a significant turnaround for the company [1] - The company's stock price has increased by 170%, yet it still trades at a modest forward P/E ratio of 8x, indicating potential value [1] Financial Performance - The transition to profitability occurred rapidly, suggesting effective management and operational improvements [1] - The forward P/E ratio of 8x implies that the stock may be undervalued compared to its earnings potential [1]
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
Prnewswire· 2025-08-26 02:00
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On August 15, 2025, ...
OS Therapies Terminates Equity Line of Credit
Newsfile· 2025-08-26 01:51
Core Viewpoint - OS Therapies has terminated its Equity Purchase Agreement with Square Gate Capital Master Fund, effective August 26, 2025, and has successfully raised $4.2 million through a warrant exercise inducement and exchange offering to fund operations into mid-2026 [1][2]. Group 1: Financial Developments - The termination of the Equity Purchase Agreement (ELOC) with Square Gate Capital Master Fund is effective August 26, 2025 [1]. - The company raised $4.2 million in gross proceeds from a recent warrant exercise inducement and exchange offering, which will support operations through mid-2026 [2]. Group 2: Clinical Trials and Product Development - The treatment phases of the Phase 2b OST-HER2 clinical trial in osteosarcoma and the Phase 1b OST-504 clinical trial in prostate cancer are now complete, leading to a projected monthly burn rate in the second half of 2025 that is significantly lower than in the first half [3]. - OS Therapies plans to allocate capital primarily to drive towards approval for OST-HER2 in osteosarcoma while analyzing data from OST-504 for future development steps [3]. Group 3: Company Overview and Product Pipeline - OS Therapies is focused on developing treatments for osteosarcoma and other solid tumors, with its lead asset, OST-HER2, leveraging immune-stimulatory effects to target the HER2 protein [4]. - OST-HER2 has received multiple designations from the U.S. FDA, including Rare Pediatric Disease Designation and Fast-Track designation, and the company plans to submit a Biologics Licensing Application (BLA) for OST-HER2 in 2025 [4]. - The company is also advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which utilizes proprietary technology for enhanced delivery of therapeutic payloads [5].
让更多创新药在南京“首发”
Nan Jing Ri Bao· 2025-08-25 23:35
挂牌运营八个多月,南京生物医药分中心已落地项目四十五个 让更多创新药在南京"首发" 研发人员正在600兆核磁机器上进行加样检测工作。 蹲点点位:全国高校生物医药区域技术转移转化中心(江苏南京) 8月20日上午9时,中国药科大学药学院教授韩思飞早早来到全国高校生物医药区域技术转移转化中心 (江苏南京)的质谱分析实验室,在技术人员的帮助下进行研发试验。从今年3月接洽开始,到5月公司 正式注册落户,再到9月公司即将全面运转,韩思飞教授最新的研发成果正一步步从实验室走上生产 线。 推动更多高校的科技成果转化为现实生产力,让高"研值"带来高产值,韩思飞教授的项目并非个例。南 京生物医药分中心挂牌运营8个多月以来,对接全国76家高校、落地项目45个、筛选后入库项目1395 个。更为难得的是,分中心建立了全链条服务体系,以完善的硬件和软件,吸引着更多的优质项目慕名 而来。 当初的创业设想 正一步步实现 韩思飞教授与研发人员一起探讨实验方案。 全国高校生物医药区域技术转移转化中心(江苏南京)。 作为分中心的载体之一,位于星火路的江北 新区现代产业创新中心将陆续投用。 □ 南京日报/紫金山新闻记者 李都 蹲点主题:推动科技成果 ...
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters
Seeking Alpha· 2025-08-25 22:01
Group 1 - The article discusses Stephen's background as a Registered Nurse (RN) and an MBA, highlighting his unique approach to analyzing healthcare and tech stocks through the "Dizzy Framework" [1] - The "Dizzy Framework" is designed to mitigate common behavioral errors in investment, such as chasing market noise and adhering too rigidly to prior beliefs, emphasizing the importance of quality and timing of information [1] - Influences on Stephen's investment philosophy include concepts from "Superforecasting" and "Fooled by Randomness," which inform his disciplined and patient investment approach [1]
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
GlobeNewswire News Room· 2025-08-25 21:55
Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 15, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Unicycive Therapeutics, Inc.(UNCY) Shareholders
GlobeNewswire News Room· 2025-08-25 21:34
Core Viewpoint - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. due to alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2] - It is also alleged that the regulatory prospects of the oxylanthanum carbonate new drug application were exaggerated [2] - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 14, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]